menu
    • menu
    [{"orgOrder":0,"company":"Tachyon Therapeutics","sponsor":"Cirm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"TACH101","moa":"KDM4 histone demethylase","graph1":"Oncology","graph2":"Phase I","graph3":"Tachyon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tachyon Therapeutics \/ Cirm","highestDevelopmentStatusID":"6","companyTruncated":"Tachyon Therapeutics \/ Cirm"},{"orgOrder":0,"company":"Tachyon Therapeutics","sponsor":"Veblen Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"TACH101","moa":"KDM4 histone demethylase","graph1":"Oncology","graph2":"Phase I","graph3":"Tachyon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tachyon Therapeutics \/ Veblen Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Tachyon Therapeutics \/ Veblen Ventures"}]

    Find Clinical Drug Pipeline Developments & Deals by Tachyon Therapeutics

    Menu

    Tachyon Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Tachyon Therapeutics

                            U.S.A arrow
                            AMWC Asia-TDAC
                            Not Confirmed

                            Tachyon Therapeutics

                            U.S.A arrow
                            AMWC Asia-TDAC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TACH101

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Cirm

                            Deal Size : $7.1 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Tachyon Receives Funding from CIRM for a Phase 1 Clinical Study of TACH101, a First-in-Class KDM4 Inhibitor, i...

                            Details : The funding will be used to support a Phase 1 clinical study of TACH101 in patients with advanced solid tumors, with an expansion phase planned for gastrointestinal cancers, including microsatellite instability high (MSI-H) colorectal cancer (CRC).

                            Product Name : TACH101

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 03, 2023

                            Lead Product(s) : TACH101

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Cirm

                            Deal Size : $7.1 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Tachyon Therapeutics

                            U.S.A arrow
                            AMWC Asia-TDAC
                            Not Confirmed

                            Tachyon Therapeutics

                            U.S.A arrow
                            AMWC Asia-TDAC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TACH101

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Veblen Ventures

                            Deal Size : $11.6 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Tachyon Announces Financing and Start of Clinical Study of First-in-Class KDM4 Inhibitor for Advanced Cancers

                            Details : The net financing will support the Phase 1 study in advanced solid tumors for TACH101, a small molecule, KDM4 histone demethylase inhibitor and to advance Company’s pipeline of emerging oncology candidates targeting previously unexplored mechanisms of ...

                            Product Name : TACH101

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 03, 2023

                            Lead Product(s) : TACH101

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Veblen Ventures

                            Deal Size : $11.6 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth